All I'm saying is Novartis looked under the hood and walked away.
..... yes on the FDA Supports Accelerated Approval for CHF thread and 'inferring' that Novartis walked away from everything when their partnership agreement was only for Remestemcel-L and COVID-19 ARDS, which most docs would know has nothing to do with the Rexlemestrocel-L CHF indication .... as you were - I can't be bothered
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-432
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.09 | $1.03 | $7.869M | 7.571M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16411 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 3952 | 2 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
-0.040 ( 3.65 %) |
||||
| Open | High | Low | Volume | ||
| $1.07 | $1.08 | $1.03 | 1907057 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| MSB (ASX) Chart |